| Patient characteristics . | n = 90 . |
|---|---|
| Age at diagnosis, yr (IQR) | 64 (55–70) |
| Gender | |
| Male (%) | 47 (52) |
| Female (%) | 43 (48) |
| Race | |
| White (%) | 75 (97) |
| Black (%) | 2 (3) |
| Ethnicity | |
| Hispanic (%) | 75 (97) |
| Non-Hispanic (%) | 2 (3) |
| IDH-1 status | |
| WT (%) | 84 (93) |
| Mutated (%) | 6 (7) |
| MGMT promoter | |
| Unmethylated (%) | 53 (59) |
| Methylated (%) | 34 (38) |
| P53 stain, % (IQR) | 5 (2–20%) |
| Ki67, % (IQR) | 30 (16–40%) |
| Preoperative steroid use, n (%) | 85 (94) |
| Median overall survival, mo (95% confidence interval) | 15 (12–19) |
| 1-yr survival, n at risk (survival probability) | 37 (59%) |
| 2-yr survival, n at risk (survival probability) | 12 (26%) |
| Patient characteristics . | n = 90 . |
|---|---|
| Age at diagnosis, yr (IQR) | 64 (55–70) |
| Gender | |
| Male (%) | 47 (52) |
| Female (%) | 43 (48) |
| Race | |
| White (%) | 75 (97) |
| Black (%) | 2 (3) |
| Ethnicity | |
| Hispanic (%) | 75 (97) |
| Non-Hispanic (%) | 2 (3) |
| IDH-1 status | |
| WT (%) | 84 (93) |
| Mutated (%) | 6 (7) |
| MGMT promoter | |
| Unmethylated (%) | 53 (59) |
| Methylated (%) | 34 (38) |
| P53 stain, % (IQR) | 5 (2–20%) |
| Ki67, % (IQR) | 30 (16–40%) |
| Preoperative steroid use, n (%) | 85 (94) |
| Median overall survival, mo (95% confidence interval) | 15 (12–19) |
| 1-yr survival, n at risk (survival probability) | 37 (59%) |
| 2-yr survival, n at risk (survival probability) | 12 (26%) |
IDH, isocitrate dehydrogenase; IQR, interquartile range; MGMT, O[6]-methylguanine-DNA.